Lidocaine Hydrochloride Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Lidocaine Hydrochloride Market Analysis
The lidocaine hydrochloride market size is expected to record a CAGR of 4.1% during the forecast period.
COVID-19 had an impact on the growth of the market during the pandemic period owing to the potential anesthetic and anti-inflammatory properties of lidocaine in COVID-19. For instance, according to the Springer article published in March 2021, it was proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patient's lungs, and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel coronavirus. Thus, the potential benefits of lidocaine hydrochloride in the treatment of COVID-19 patients had an impact on the growth of the market. Moreover, the relaxation of strict regulations on surgical procedures in the post-pandemic period and the resumption of services are expected to drive the demand for lidocaine hydrochloride, thereby boosting market growth over the forecast period.
The increase in the number of surgical procedures performed worldwide, including dental procedures, cosmetic surgeries, and plastic surgeries, is expected to promote growth owing to the vast anesthetic usage of lidocaine hydrochloride in the surgeries. In addition, the rise in chronic and acute pain-related disorders and various benefits associated with lidocaine hydrochloride are some of the major factors driving the market growth. For instance, as per the Aesthetics Society 2021 report, there were around 3.2 million aesthetic procedures performed in 2021 in the United States. Additionally, the prevalence of pain-related disorders such as epilepsy and heart arrhythmia among the global population is also one of the driving factors for the growth of the market owing to the anti-inflammatory and pain reduction properties of lidocaine hydrochloride. For instance, as per the WHO data published in February 2022, around 50 million people worldwide have epilepsy, and an estimated 5 million people are diagnosed with epilepsy each year. Furthermore, additionally, the NCBI article published in May 2021 mentioned that in Europe, prevalent atrial fibrillation cases were expected to reach 14 million by 2060. Such prevalence of target diseases among the global population is expected to drive the growth of the studied market over the forecast period.
Additionally, the rising product launches by various market players are also expected to contribute to the growth of the market over the forecast period. For instance, in April 2022, Alembic Pharmaceuticals, wholly-owned Aleor Dermaceuticals, received final approval from the United States Food and Drug Administration for Lidocaine for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery. Further, owing to their safety profile and proven efficacy, lidocaine patches have been recommended as first-line therapy for the treatment of neuropathic pain in older patients, as well as those suffering from shingles, and this is expected to boost the market growth during the forecast period. Therefore, due to the aforementioned factors, the lidocaine hydrochloride market is expected to grow over the forecast period. However, the risk associated with lidocaine hydrochloride is expected to restrain the growth of the market during the forecast period.
Lidocaine Hydrochloride Market Trends
This section covers the major market trends shaping the Lidocaine Hydrochloride Market according to our research experts:
Dental Procedure Segment is Expected to Hold Significant Share in the Market During the Forecast Period
The dental procedure segment is expected to record a lucrative CAGR during the forecast period. This is primarily attributed to the extensive usage of lidocaine hydrochloride injectables in different dental surgical procedures. For instance, the article published in Nature Journal in July 2021 mentioned that the buccal infiltration technique using lidocaine plus lingual anesthesia might be a good alternative in anesthetizing mandibular premolar teeth before their extraction. An increase in the prevalence of dental disorders, coupled with the growing number of surgeries performed, is the key driving factor for this segment. For instance, as per the WHO data published in March 2022, severe periodontal diseases were estimated to affect around 14% of the global adult population. Similarly, the research study published in Frontiers in April 2021 mentioned that the overall pooled prevalence of dental caries was found to be 45.7% in East Africa. Such a high prevalence of various dental disorders is expected to drive the demand for lidocaine hydrochloride during treatment procedures, thereby boosting segment growth.
Additionally, the increasing number of dental consultations is also expected to contribute to the growth of the studied segment. For instance, the data published by NHS in 2022 mentioned that in England, nearly 15.8 million adults visited an NHS dentist till December 2021, and over 5.1 million children visited an NHS dentist by December 2021. Thus, the rise in dental visits is also expected to contribute to the growth of the studied segment, as lidocaine hydrochloride is used as a local anesthetic in dental procedures.
North America is Expected to Hold Significant Share in the Market During the Forecast Period
North America is expected to show healthy growth in the market over the forecast period owing to the presence of major market players. The efficiency of lidocaine hydrochloride in various surgical procedures is expected to drive the growth of the market in this region. For instance, the data published by NIH in June 2021 mentioned that lidocaine helps numb the area during and after the liposuction surgery, and it may be the only anesthesia needed for the procedures. Such usage of lidocaine in surgical procedures is expected to contribute to the growth of the market in this region, attributed to the high volume of surgeries.
Furthermore, the growth of the market can be attributed to the increasing volume of various surgical and cosmetic procedures, advancements in surgical procedures, and the growing use of lidocaine hydrochloride in postoperative pain management. For instance, according to the aesthetic society report published in 2022, about 458,628 liposuction procedures, 362,346 breast augmentation procedures, and 146,761 breast implant removal procedures were performed among women in the United States in 2021. Also, as per the OECD data published in December 2022, in Canada, approximately 54,991 hip replacement surgical procedures were performed in 2021. Moreover, the expanding geriatric population is anticipated to drive the number of surgical procedures performed in the region, thereby promising growth over the forecast period. Thus, the factors mentioned above are expected to drive the market's demand for development of the market during the forecast period in this region.
Lidocaine Hydrochloride Industry Overview
The lidocaine hydrochloride market is moderately competitive and consists of several major players. Some of the key players include companies such as Alanza Inc, Amphastar Pharmaceuticals, Inc., Cirondrugs, Mahendra Chemicals, Medexim India, Merck KGaA, Nortec Qumica, and Pfizer Inc. Investment for the development of effective and long-acting products with lesser adverse effects and improving geographical penetration through partnerships and collaborations are the key strategies adopted by the companies to increase their market shares.
Lidocaine Hydrochloride Market Leaders
-
Pfizer Inc
-
Merck KGaA
-
MAHENDRA CHEMICALS
-
Nortec Qumica
-
Cirondrugs
*Disclaimer: Major Players sorted in no particular order
Lidocaine Hydrochloride Market News
- August 2022: Scilex Holding Company received the FDA fast-track designation for its investigational drug and device product candidate, SP-103. SP-103 is a non-opioid triple-strength, non-aqueous lidocaine topical system for treating acute lower back pain.
- April 2022: Mad Rabbit launched Numbing creams to relieve pain in just one application. The formulation features 5% lidocaine, a local anesthetic that numbs the area applied by blocking the pain receptors in the skin.
Lidocaine Hydrochloride Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increase in Prevalence of Target Diseases
- 4.2.2 Rising Demand for Anesthetics in Surgeries
-
4.3 Market Restraints
- 4.3.1 Risk Associated with Lidocaine Hydrochloride
-
4.4 Porter Five Forces
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Dosage Form
- 5.1.1 Creams
- 5.1.2 Patches
- 5.1.3 Injectables
- 5.1.4 Other Dosage Forms
-
5.2 By Application
- 5.2.1 Heart Arrhythmia
- 5.2.2 Dental Procedure
- 5.2.3 Epilepsy
- 5.2.4 Other Applications
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Alanza Inc
- 6.1.2 Amphastar Pharmaceuticals Inc.
- 6.1.3 Cirondrugs
- 6.1.4 Mahendra Chemicals
- 6.1.5 Medexim India
- 6.1.6 Merck KGaA
- 6.1.7 Nortec Qumica
- 6.1.8 Pfizer Inc.
- 6.1.9 Scilex Holding Company
- 6.1.10 Himatsu Pharmaceutical Co., Ltd
- 6.1.11 Jiangsu Tianji Pharmaceutical Co Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityLidocaine Hydrochloride Industry Segmentation
As per the scope of the report, lidocaine hydrochloride is an anesthetic compound that acts by stabilizing the neuronal membrane by inhibiting ionic fluxes. It is largely utilized as a local anesthetic compound for surgical procedures by nerve block or infiltration techniques to prevent and relieve pain during surgical procedures. The Lidocaine Hydrochloride Market is Segmented by Dosage Form (Creams, Injectables, Patches, and Other Dosage Forms), Application (Heart Arrhythmia, Dental Procedure, Epilepsy, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Dosage Form | Creams | |
| Patches | ||
| Injectables | ||
| Other Dosage Forms | ||
| By Application | Heart Arrhythmia | |
| Dental Procedure | ||
| Epilepsy | ||
| Other Applications | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Lidocaine Hydrochloride Market Research FAQs
What is the current Lidocaine Hydrochloride Market size?
The Lidocaine Hydrochloride Market is projected to register a CAGR of 4.10% during the forecast period (2024-2029)
Who are the key players in Lidocaine Hydrochloride Market?
Pfizer Inc , Merck KGaA , MAHENDRA CHEMICALS , Nortec Qumica and Cirondrugs are the major companies operating in the Lidocaine Hydrochloride Market.
Which is the fastest growing region in Lidocaine Hydrochloride Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Lidocaine Hydrochloride Market?
In 2024, the North America accounts for the largest market share in Lidocaine Hydrochloride Market.
What years does this Lidocaine Hydrochloride Market cover?
The report covers the Lidocaine Hydrochloride Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Lidocaine Hydrochloride Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Respiratory Protection Equipment Industry Report
Statistics for the 2024 Respiratory Protection Equipment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Respiratory Protection Equipment analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
